The present invention relates to solid amorphous and crystalline forms of ibandronate sodium.

Claim:

What is claimed is:

1. A crystalline form of ibandronate sodium selected from the group consisting of: g) the crystalline form of ibandronate sodium characterized by x-ray reflections at about4.6, 9.2, 18.3, 19.6, and 25.6.+-.0.2.degree. 2.theta.; r) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.2, 25.9, 26.7, 31.1, and 37.2.+-.0.2.degree. 2.theta.; and u) the crystalline form of ibandronatesodium characterized by x-ray reflections at about 6.2, 15.7, 26.3, 32.6, and 35.6 .+-.0.2.degree. 2.theta..

2. The crystalline form of ibandronate sodium of claim 1, characterized by x-ray reflections at about 4.6, 9.2, 18.3, 19.6, and 25.6.+-.0.2.degree. 2.theta., denominated Form J, and further characterized by x-ray reflections at about 17.5,18.9, 21.7, 22.9, and 29.5.+-.0.2.degree. 2.theta..

3. The crystalline form of ibandronate sodium of claim 2 having a powder x-ray diffraction diagram substantially as shown in FIG. 7.

4. The crystalline form of ibandronate sodium of claim 1, characterized by x-ray reflections at about 6.2, 25.9, 26.7, 31.1, and 37.2.+-.0.2.degree. 2.theta., denominated Form QQ, and further characterized by x-ray reflections at about 16.9,17.3, 21.5, 24.7, and 29.2.+-.0.2.degree. 2.theta..

5. The crystalline form of ibandronate sodium of claim 4 having a powder x-ray diffraction diagram substantially as shown in FIG. 18.

6. The crystalline form of ibandronate sodium of claim 4 having a particle size distribution of not more than 100.mu..

7. The crystalline form of ibandronate sodium of claim 6 having a particle size distribution of not more than 60.mu..

8. The crystalline form of ibandronate sodium of claim 1, characterized by x-ray reflections at about 6.2, 15.7, 26.3, 32.6, and 35.6.+-.0.2.degree. 2.theta., denominated Form T, and further characterized by x-ray reflections at about 17.6,19.4, 26.9, 31.7, and 38.7.+-.0.20.degree. 2.theta..

9. The crystalline form of ibandronate sodium of claim 8 having a powder x-ray diffraction diagram substantially as shown in FIG. 21.